Open AccessChemotherapy-associated Posterior Reversible Encephalopathy Syndrome
Author(s) -
Joan How,
Margaret Blattner,
Susan A. Fowler,
Andrea WangGillam,
Suzanne E. Schindler
Publication year - 2016
Publication title -
the neurologist/the neurologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.43
H-Index - 60
eISSN - 2331-2637
pISSN - 1074-7931
DOI - 10.1097/nrl.0000000000000105
Subject(s) - medicine , posterior reversible encephalopathy syndrome , vincristine , prednisone , rituximab , cyclophosphamide , chemotherapy , methotrexate , encephalopathy , chop , hyperintensity , gastroenterology , surgery , lymphoma , magnetic resonance imaging , radiology
There are increasing reports of posterior reversible encephalopathy syndrome (PRES) associated with the use of chemotherapeutic agents. Recognition of PRES is crucial given its reversibility with appropriate supportive management. We report a patient presenting with PRES after treatment with Rituximab, Cyclophosphamide, Hydroxydaunorubicin/Adriamycin, Oncovin/Vincristine, Prednisone (R-CHOP) and intrathecal methotrexate. We also perform a systematic review of the literature on chemotherapy-associated PRES.